- About us
- About Vaccines
- Media centre
- Become a member
- VE Day 2013
How long for a vaccine to reach European Population? 6,4 years is the median time lag between marketing authorisation and effective population access
Vaccines Europe acts as the cohesive voice of the Europe-based vaccine industry sector and is a trusted partner for public authorities. Find out more about our association and contribution to Europe.
With 47% growth in R&D investment over the past eight years and over 70% of current R&D projects based on new antigens and new combinations, Vaccines Europe members highly contribute to innovation.
The vaccine industry is actively engaged in research & development of new vaccines that target diseases difficult to treat such as HIV/AIDS, cancer, Alzheimer and malaria among others, in view of improving public health.
As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe and is currently expanding to SMEs.
Find out more about our services, the opportunites we offer and how to become a member.
Vaccines Europe is part of a newly launched five-year EUR 10.7 million IMI (Innovative Medicines Initiative) project aiming to develop a pan-European framework for improved assessment of vaccines benefits and risks. This would represent a landmark step with regards to current practice, where although vaccines undergo rigorous safety testing before regulatory approval, efforts to monitor the coverage, benefits and risks of vaccines post-marketing authorisation remain fragmented across actors and countries. Read more…
Vaccines Europe is currently cooperating with SAATI for the launch and dissemination of a SAATI commissioned EU Report Card on the state of play of adult immunisation in the EU27 and the benefits of implementing a life course approach to vaccination.
The report consolidates existing research on the incidence of the main vaccine-preventable diseases in Europe and bringing new evidence on the economic benefits of adult vaccination. It also aims to shed light on the gaps existing in adult immunisation policies in EU Member States Read more…